CHIEMEZIE OKONKO: Open Payments
NPI 1881247229 · INGLEWOOD, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,752 in 57 payments from 13 companies in 2025. Trend: 2023 $1,223 · 2024 $1,467 · 2025 $2,752
Food & beverage: $2,529Education: $223
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 26 | $944 |
| Janssen Pharmaceuticals, Inc | 9 | $652 |
| Otsuka America Pharmaceutical, Inc. | 6 | $231 |
| Braeburn Inc. | 4 | $190 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $171 |
| Alkermes, Inc. | 1 | $123 |
| Axsome Therapeutics, Inc. | 1 | $123 |
| Janssen Biotech, Inc. | 1 | $123 |
| Novo Nordisk Inc | 1 | $105 |
| E.R. Squibb & Sons, L.L.C. | 1 | $25 |
Products named: UZEDY, INVEGA SUSTENNA, SPRAVATO, BRIXADI, CAPLYTA, REXULTI, LYBALVI, Auvelity.
Industry payments across CA — which companies pay providers there.
